Rockland Trust’s Summit Therapeutics SMMT Stock Holding History

Rockland Trust’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-400,000	Closed	-$8.51M	–	310
2025 Q2	$8.51M	Buy	+400,000	New	+$9.12M	0.41%	69

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Rockland Trust's SMMT Position: Q3 2025 in Review

Rockland Trust sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 400,000 shares — an estimated $8.51M sold.

Rockland Trust first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $8.51M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

Rockland Trust reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
Rockland Trust sold 400,000 Summit Therapeutics shares in Q3 2025, an estimated $8.51M.
Rockland Trust first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
Rockland Trust's Summit Therapeutics position peaked at $8.51M in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Rockland Trust's 13F filing for Q3 2025, filed 6 Nov 2025.